Draft:KVK-Tech
 | Review waiting, please be patient.
This may take 4 weeks or more, since drafts are reviewed in no specific order. There are 494 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2004 |
Area served | International |
| Products | Pharmaceutical |
| Services | Drug development and manufacturing |
| Website | www |
KVK-Tech, Inc. is a pharmaceutical company based in Newtown, Pennsylvania. The company develops and manufactures generic and branded pharmaceutical products, primarily in oral solid dosage form.
History
[edit]KVK-Tech was founded in 2004. The company produces generic medications for a variety of conditions, including hypertension, diabetes, and attention-deficit/hyperactivity disorder (ADHD). In 2016, the FDA approved Lomaira (phentermine hydrochloride tablets USP, 8 mg), a low-dose formulation of phentermine for weight management in adults with a body mass index (BMI) of 30 kg/m² or more, or 27 kg/m² or more with at least one weight-related comorbidity such as hypertension or type 2 diabetes.[1] In 2023, the company announced that Lomaira had been registered for sale in Mexico through a partnership with Medix.[2]
In 2024, KVK-Tech stated that it had expanded its research and development (R&D) facilities to support the development of complex generics and drug delivery technologies.[3]
Facilities and expansion
[edit]In 2023, KVK-Tech acquired a 200,000-square-foot facility in Newtown, Pennsylvania, previously operated by Lockheed Martin to increase manufacturing capacity and support additional research and development activities.[4][5]
In 2024, the company announced a distribution agreement to introduce its products to the Canadian market.
Partnerships
[edit]In 2023, the company partnered with Sen-Jam Pharmaceutical to develop and distribute pharmaceutical products related to pain and inflammation.[6]
Community programs
[edit]Since 2017, KVK-Tech has collaborated with the Council Rock School District in Bucks County, Pennsylvania, on science, technology, engineering, and mathematics (STEM) education programs.[7] In 2024, the company began offering scholarships to local students pursuing STEM-related fields.[8]
References
[edit]- ^ https://www.bizjournals.com/philadelphia/news/2016/09/21/fda-approves-lomaira-kvk-tech-weight-loss-pill.html
- ^ "KVK Tech's Lomaira has successfully completed registration in Mexico through its partner Medix" (Press release).
- ^ https://www.pharmaceuticalcommerce.com/view/kvk-tech-bolsters-r-d-to-tackle-complex-generics
- ^ "KVK-Tech Signs Agreement of Sale to Acquire Lockheed-Martin Facility in Newtown, PA | Fierce Pharma". 5 March 2015.
- ^ "Generic drugmaker snaps up Lockheed site with big expansion plans | Fierce Pharma". 5 March 2015.
- ^ "Sen-Jam Pharmaceutical Enters Strategic Partnership with KVK-Tech". 10 April 2024.
- ^ "BUILDING COGNITIVE CONNECTIONS: Newtown-based KVK Tech Inc. Partners with Council Rock to develop the next generation of scientists". May 2017.
- ^ https://www.buckscountycouriertimes.com/story/news/2024/09/20/kvk-tech-scholarships-stem-students/75234567007/